126 related articles for article (PubMed ID: 27262172)
21. [Mismatch repair (MMR) efficiency and MSH2 gene mutation in human colorectal carcinoma cell line COLO320HSR].
Tronov VA; Kramarenko II; Maĭorova EN; Zakharov SF
Genetika; 2007 Apr; 43(4):537-44. PubMed ID: 17555131
[TBL] [Abstract][Full Text] [Related]
22. Hyperthermia effects on Hsp27 and Hsp72 associations with mismatch repair (MMR) proteins and cisplatin toxicity in MMR-deficient/proficient colon cancer cell lines.
Sottile ML; Losinno AD; Fanelli MA; Cuello-Carrión FD; Montt-Guevara MM; Vargas-Roig LM; Nadin SB
Int J Hyperthermia; 2015; 31(5):464-75. PubMed ID: 26043026
[TBL] [Abstract][Full Text] [Related]
23. YB-1 disrupts mismatch repair complex formation, interferes with MutSα recruitment on mismatch and inhibits mismatch repair through interacting with PCNA.
Chang YW; Mai RT; Fang WH; Lin CC; Chiu CC; Wu Lee YH
Oncogene; 2014 Oct; 33(43):5065-77. PubMed ID: 24141788
[TBL] [Abstract][Full Text] [Related]
24. DNA mismatch repair (MMR) mediates 6-thioguanine genotoxicity by introducing single-strand breaks to signal a G2-M arrest in MMR-proficient RKO cells.
Yan T; Berry SE; Desai AB; Kinsella TJ
Clin Cancer Res; 2003 Jun; 9(6):2327-34. PubMed ID: 12796402
[TBL] [Abstract][Full Text] [Related]
25. Analysis of DNA mismatch repair in cellular response to DNA damage.
Gu L; Li GM
Methods Enzymol; 2006; 408():303-17. PubMed ID: 16793377
[TBL] [Abstract][Full Text] [Related]
26. Hypersensitivity to camptothecin in MSH2 deficient cells is correlated with a role for MSH2 protein in recombinational repair.
Pichierri P; Franchitto A; Piergentili R; Colussi C; Palitti F
Carcinogenesis; 2001 Nov; 22(11):1781-7. PubMed ID: 11698339
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
28. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status.
Adamsen BL; Kravik KL; De Angelis PM
Int J Oncol; 2011 Sep; 39(3):673-82. PubMed ID: 21674128
[TBL] [Abstract][Full Text] [Related]
29. Role of MutSalpha in the recognition of iododeoxyuridine in DNA.
Berry SE; Loh T; Yan T; Kinsella TJ
Cancer Res; 2003 Sep; 63(17):5490-5. PubMed ID: 14500385
[TBL] [Abstract][Full Text] [Related]
30. Mismatch repair deficiency in Lynch syndrome-associated colorectal adenomas is more prevalent in older patients.
Tanaka M; Nakajima T; Sugano K; Yoshida T; Taniguchi H; Kanemitsu Y; Nagino M; Sekine S
Histopathology; 2016 Aug; 69(2):322-8. PubMed ID: 26826556
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and clinicopathologic/molecular characteristics of mismatch repair-deficient colorectal cancer in the under-50-year-old Japanese population.
Suzuki O; Eguchi H; Chika N; Sakimoto T; Ishibashi K; Kumamoto K; Tamaru JI; Tachikawa T; Akagi K; Arai T; Okazaki Y; Ishida H
Surg Today; 2017 Sep; 47(9):1135-1146. PubMed ID: 28258479
[TBL] [Abstract][Full Text] [Related]
32. Cell-free DNA blood levels in colorectal cancer patients do not correlate with mismatch repair-proficiency.
Lazarev I; Leibovitch L; Czeiger D; Sion-Vardi N; Geffen DB; Douvdevani A; Ariad S
In Vivo; 2014; 28(3):349-54. PubMed ID: 24815837
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
[TBL] [Abstract][Full Text] [Related]
34. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
Stachelek GC; Peterson-Roth E; Liu Y; Fernandez RJ; Pike LR; Qian JM; Abriola L; Hoyer D; Hungerford W; Merkel J; Glazer PM
Mol Cancer Res; 2015 Oct; 13(10):1389-97. PubMed ID: 26116172
[TBL] [Abstract][Full Text] [Related]
35. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors.
Mensenkamp AR; Vogelaar IP; van Zelst-Stams WA; Goossens M; Ouchene H; Hendriks-Cornelissen SJ; Kwint MP; Hoogerbrugge N; Nagtegaal ID; Ligtenberg MJ
Gastroenterology; 2014 Mar; 146(3):643-646.e8. PubMed ID: 24333619
[TBL] [Abstract][Full Text] [Related]
36. HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions.
de Wind N; Dekker M; Claij N; Jansen L; van Klink Y; Radman M; Riggins G; van der Valk M; van't Wout K; te Riele H
Nat Genet; 1999 Nov; 23(3):359-62. PubMed ID: 10545954
[TBL] [Abstract][Full Text] [Related]
37. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint.
Hawn MT; Umar A; Carethers JM; Marra G; Kunkel TA; Boland CR; Koi M
Cancer Res; 1995 Sep; 55(17):3721-5. PubMed ID: 7641183
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
Pohl M; Schmiegel W
Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
[TBL] [Abstract][Full Text] [Related]
39. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of 12-lipoxygenase during baicalein-induced human lung nonsmall carcinoma H460 cell apoptosis.
Leung HW; Yang WH; Lai MY; Lin CJ; Lee HZ
Food Chem Toxicol; 2007 Mar; 45(3):403-11. PubMed ID: 17050058
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
